In tumor cells, LINC02096 inhibits the ubiquitination of histone methyltransferase MLL1, which enhances the levels of H3K4me3 in the promoter regions of PD-L1 and IDO-1, thereby undermining anti-tumor immunity (73). Here, PRDM9 is linked to neoplasm.